Publicacións en colaboración con investigadores/as de Queen Mary University of London (8)

2023

  1. Genetic and immune landscape evolution in MMR-deficient colorectal cancer

    Journal of Pathology

2021

  1. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

    The Lancet Oncology, Vol. 22, Núm. 6, pp. 858-871

  2. Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial

    European Journal of Cancer, Vol. 148, pp. 382-394

2016

  1. Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression

    Oncotarget, Vol. 7, Núm. 14, pp. 18325-18345

2014

  1. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

    Nature, Vol. 510, Núm. 7505, pp. 407-411

2013

  1. Class II Phosphoinositide 3-Kinases Contribute to Endothelial Cells Morphogenesis

    PLoS ONE, Vol. 8, Núm. 1

2012

  1. Lysophosphatidylinositol signalling: New wine from an old bottle

    Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, Vol. 1821, Núm. 4, pp. 694-705

2011

  1. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility

    Nature Genetics, Vol. 43, Núm. 8, pp. 761-767